Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OVID | Common Stock | Purchase | $50.4K | +18.2K | +0.51% | $2.76 | 3.62M | Mar 18, 2024 | Direct | F1 |
holding | OVID | Common Stock | 35.5K | Mar 18, 2024 | See Footnote | F2 |
Id | Content |
---|---|
F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.76 to $2.78 inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc., any security holder of Ovid Therapeutics Inc., or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4. |
F2 | The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse is the manager of Divo. The Reporting Person disclaims beneficial ownership of the shares held by Divo and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose. |